Cronos Group Inc (TSX:CRON) (NASDAQ:CRON) shares fell Wednesday after a trio of downgrades hit the cannabis stock.
PI Financial's Jason Zandberg and Cormack’s Jesse Pytlak each rethought their bullishness on the Toronto firm, downshifting, respectively, to Neutral from Buy and to Market Perform from Speculative Buy.
Matt Bottomley of Canaccord went a step farther, cutting his rating to Sell from Hold, citing a “soft start” to Canada’s legal cannabis market.
READ: Buds & Duds: Cronos shares tumble, Newstrike Brands soars on results
The demerits come after the cannabis investment firm posted a fourth-quarter net loss of US$116 million, US$0.06 per share, on Tuesday, compared with a $0.01 profit the previous year.
The stock sank 10% to C$24.32 on the TSX and lost more than 10% to US$18.10 on the Nasdaq.